دورية أكاديمية
Association of Concomitant Bone Resorption Inhibitors with Overall Survival among Patients with Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate with Prednisone as First-Line Therapy
| العنوان: | Association of Concomitant Bone Resorption Inhibitors with Overall Survival among Patients with Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate with Prednisone as First-Line Therapy |
|---|---|
| المؤلفون: | Francini E., Montagnani F., Nuzzo P. V., Gonzalez-Velez M., Alimohamed N. S., Rosellini P., Moreno-Candilejo I., Cigliola A., Rubio-Perez J., Crivelli F., Shaw G. K., Zhang L., Petrioli R., Bengala C., Francini G., Garcia-Foncillas J., Sweeney C. J., Higano C. S., Bryce A. H., Harshman L. C., Lee-Ying R., Heng D. Y. C. |
| المساهمون: | Francini, E., Montagnani, F., Nuzzo, P. V., Gonzalez-Velez, M., Alimohamed, N. S., Rosellini, P., Moreno-Candilejo, I., Cigliola, A., Rubio-Perez, J., Crivelli, F., Shaw, G. K., Zhang, L., Petrioli, R., Bengala, C., Francini, G., Garcia-Foncillas, J., Sweeney, C. J., Higano, C. S., Bryce, A. H., Harshman, L. C., Lee-Ying, R., Heng, D. Y. C. |
| سنة النشر: | 2021 |
| المجموعة: | Università degli Studi di Siena: USiena air |
| مصطلحات موضوعية: | Abiraterone Acetate, Aged, 80 and over, Bone Density Conservation Agent, Bone Neoplasm, Cohort Studie, Human, Kaplan-Meier Estimate, Male, Neoplasm Metastasi, Prednisone, Prostatic Neoplasms, Castration-Resistant, Registrie, Retrospective Studies |
| الوصف: | Importance: Bone resorption inhibitors (BRIs) are recommended by international guidelines to prevent skeletal-related events (SREs) among patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Abiraterone acetate with prednisone is currently the most common first-line therapy for the treatment of patients with mCRPC; however, the clinical impact of the addition of BRIs to abiraterone acetate with prednisone in this disease setting is unknown. Objective: To evaluate the association of the use of concomitant BRIs with overall survival (OS) and time to first SRE among patients with mCRPC and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. Design, Setting, and Participants: This retrospective cohort study collected data from 745 consecutive patients who began receiving abiraterone acetate with prednisone as first-line therapy for mCRPC with bone metastases between January 1, 2013, and December 31, 2016. Data were collected from 8 hospitals in Canada, Europe, and the US from June 15 to September 15, 2019. Exposures: Patients were classified by receipt vs nonreceipt of concomitant BRIs and subclassified by volume of disease (high volume or low volume, using definitions from the Chemohormonal Therapy Vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED] E3805 study) at the initiation of abiraterone acetate with prednisone therapy. Main Outcomes and Measures: The primary end point was OS. The secondary end point was time to first SRE. The Kaplan-Meier method and Cox proportional hazards models were used. Results: Of the 745 men (median age, 77.6 years [interquartile range, 68.1-83.6 years]; 699 White individuals [93.8%]) included in the analysis, 529 men (71.0%) received abiraterone acetate with prednisone alone (abiraterone acetate cohort), and 216 men (29.0%) received abiraterone acetate with prednisone plus BRIs (BRI cohort). A total of 420 men (56.4%) had high-volume disease, and 276 men (37.0%) had ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34292336; info:eu-repo/semantics/altIdentifier/wos/WOS:000676010700001; volume:4; issue:7; firstpage:1; lastpage:13; numberofpages:13; journal:JAMA NETWORK OPEN; http://hdl.handle.net/11365/1189295Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85111167193; https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782169Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299314Test/ |
| DOI: | 10.1001/jamanetworkopen.2021.16536 |
| الإتاحة: | https://doi.org/10.1001/jamanetworkopen.2021.16536Test http://hdl.handle.net/11365/1189295Test https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782169Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299314Test/ |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.B210BD5F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1001/jamanetworkopen.2021.16536 |
|---|